[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

4 clusters · 9 sources · 35 days · First seen · Last updated

FDA, Japan, and China approve Orzeyful for narcolepsy

Overview

The U.S. Food and Drug Administration has approved Takeda’s Orzeyful (oveporexton), the first oral orexin-2 receptor agonist for adults with narcolepsy type 1. Unlike previous treatments that manage symptoms, Orzeyful targets the underlying biological loss of orexin signaling to regulate sleep and wake cycles.

Clinical trials involving 273 patients demonstrated that the medication significantly improved wakefulness and reduced symptoms such as cataplexy, sleep paralysis, and hallucinations. Reported side effects include insomnia, increased saliva production, and urinary urgency or frequency.

Following the approval, the Drug Enforcement Administration (DEA) is reviewing the drug to assess its potential for addiction. Takeda’s leadership anticipates the medication will receive a schedule IV designation, suggesting a low potential for abuse.

Expanding its regulatory footprint, Takeda announced that the Japanese Ministry of Health, Labour and Welfare has also approved Orzeyful for treating narcolepsy type 1 in adults. As a first-in-class oral orexin receptor 2 agonist, it is the only medicine in Japan indicated to treat the disease holistically. The drug was originally discovered in Takeda’s laboratories in Japan, and the company is preparing for its domestic launch.

Orzeyful has since received further regulatory approval in China from the National Medical Products Administration. In China, the therapy is approved for use in adults and adolescents aged 16 and older.

Entities

Orzeyful · Takeda · Orzeyful (oveporexton) · Drug Enforcement Administration · Ministry of Health, Labour and Welfare

Timeline

  1. 2 days ago

    [HEALTH] 2 sources
    Orzeyful receives global approvals for narcolepsy type 1 treatment

    Orzeyful (oveporexton) has secured regulatory approvals in the US, Japan, and China as a first-in-class oral treatment targeting the underlying orexin deficiency in narcolepsy type 1.

  2. 19 days ago

    [HEALTH] 4 sources
    Takeda's ORZEYFUL approved in Japan for narcolepsy type 1

    Japan has approved Takeda’s ORZEYFUL (oveporexton) for treating adults with narcolepsy type 1, marking it as a first-in-class oral orexin receptor 2 agonist.

  3. 24 days ago

    [HEALTH] 2 sources
    FDA approves Orzeyful to treat narcolepsy type 1

    The FDA has approved Orzeyful (oveporexton), a new drug for narcolepsy type 1 that targets the orexin pathway to improve daytime alertness and reduce cataplexy episodes.

  4. about 1 month ago

    [HEALTH] 11 sources
    FDA Approves Orzeyful, First Orexin-Targeting Drug for Narcolepsy Type 1

    The FDA approved Takeda’s oral orexin‑2 agonist Orzeyful (oveporexton) for adults with narcolepsy type 1, the first drug to restore orexin signaling and treat the disorder’s full symptom spectrum.

Sources

aijourn.com · goodnewsnetwork.org · healthbenefitstimes.com · imfarmacias.es · infinitynews.it · pharmaceutical-business-review.com · sleepreviewmag.com · sleepworldmagazine.com · TIME.com

This summary has been updated 2 times: see revision history